Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study — M. Bhushan (2001) | RDL Network
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study
Article 2001 en
Authors
MB
M. Bhushan
AB
A. David Burden
KM
Kathleen McElhone
Abstract
1 min read
The results of this pilot study suggest that liarozole 75 mg twice daily is an effective and well-tolerated therapy for PPP. In addition, the pharmacokinetics of liarozole may help to circumvent side-effects associated with synthetic retinoids and allow its use in premenopausal women.
Emanuela Palmerini, S. Veltkamp, H. Gelderblom, Javier Martín‐Broto, A. Sebio García, M. Van de Sande, Gabriel Tinoco, Elyse Seltzer, Matthew Davies, Jean Yves Blay
Leopoldo Villegas, Rose McGready, Mg Htway, Moo Kho Paw, Mupawjay Pimanpanarak, Ratree Arunjerdja, Samuel Jacher Viladpai‐nguen, Brian Greenwood, Sir Nicholas White, François Nosten
Alice B. Gottlieb, Christopher Em Griffiths, Vincent Ho, M. Lahfa, Ulrich Mrowietz, Dédée F. Murrell, Ortonne Jp, Gail Todd, Robert Cherill, I. N. Marks, Shahram Emady‐Azar, C. Paul
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.